Stocks & Investing
Stocks and Investing
Stocks and Investing
Tue, September 19, 2023
[ Tue, Sep 19th 2023
] - WOPRAI
[ Tue, Sep 19th 2023
] - WOPRAI
[ Tue, Sep 19th 2023
] - WOPRAI
[ Tue, Sep 19th 2023
] - WOPRAI
[ Tue, Sep 19th 2023
] - WOPRAI
[ Tue, Sep 19th 2023
] - WOPRAI
[ Tue, Sep 19th 2023
] - WOPRAI
[ Tue, Sep 19th 2023
] - WOPRAI
[ Tue, Sep 19th 2023
] - WOPRAI
[ Tue, Sep 19th 2023
] - WOPRAI
[ Tue, Sep 19th 2023
] - WOPRAI
[ Tue, Sep 19th 2023
] - WOPRAI
[ Tue, Sep 19th 2023
] - WOPRAI
[ Tue, Sep 19th 2023
] - WOPRAI
[ Tue, Sep 19th 2023
] - WOPRAI
[ Tue, Sep 19th 2023
] - WOPRAI
[ Tue, Sep 19th 2023
] - WOPRAI
[ Tue, Sep 19th 2023
] - WOPRAI
[ Tue, Sep 19th 2023
] - WOPRAI
[ Tue, Sep 19th 2023
] - WOPRAI
[ Tue, Sep 19th 2023
] - WOPRAI
[ Tue, Sep 19th 2023
] - WOPRAI
[ Tue, Sep 19th 2023
] - WOPRAI
[ Tue, Sep 19th 2023
] - WOPRAI
[ Tue, Sep 19th 2023
] - WOPRAI
[ Tue, Sep 19th 2023
] - WOPRAI
[ Tue, Sep 19th 2023
] - WOPRAI
[ Tue, Sep 19th 2023
] - WOPRAI
[ Tue, Sep 19th 2023
] - WOPRAI
Raghuram Selvaraju Reiterated (ACRS) at Strong Buy and Held Target at $43 on, Sep 19th, 2023
Raghuram Selvaraju of HC Wainwright & Co., Reiterated "Aclaris Therapeutics, Inc." (ACRS) at Strong Buy and Held Target at $43 on, Sep 19th, 2023.
Raghuram has made no other calls on ACRS in the last 4 months.
There is 1 other peer that has a rating on ACRS. Out of the 1 peers that are also analyzing ACRS, 0 agree with Raghuram's Rating of Hold.
This is the rating of the analyst that currently disagrees with Raghuram
- Alex Thompson of "Stifel" Maintained at Strong Buy with Increased Target to $20 on, Thursday, September 14th, 2023
